Security Snapshot

NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) Institutional Ownership

CUSIP: G6674U108

13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

237

Shares (Excl. Options)

95,516,854

Price

$12.93

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Ordinary Shares, no par value per share
Symbol
NVCR on Nasdaq
Shares outstanding
115,301,000
Price per share
$10.55
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
95,516,854
Total reported value
$1,235,376,652
% of total 13F portfolios
0%
Share change
+4,470,404
Value change
+$57,865,507
Number of holders
237
Price from insider filings
$10.55
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • NVCR - NovoCure Ltd - Ordinary Shares, no par value per share is tracked under CUSIP G6674U108.
  • 237 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 237 to 89 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,235,376,652 to $212,895,889.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 237 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP G6674U108?
CUSIP G6674U108 identifies NVCR - NovoCure Ltd - Ordinary Shares, no par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Soleus Capital Master Fund, L.P. 9.1% +19% $110,694,725 +$20,696,209 10,492,391 +23% Soleus Capital Master Fund, L.P. 31 Mar 2026
BlackRock, Inc. 8.3% $168,501,151 9,083,620 BlackRock, Inc. 31 Mar 2025
VANGUARD PORTFOLIO MANAGEMENT LLC 5.6% $69,105,935 6,339,994 Vanguard Portfolio Management 31 Mar 2026
Capital World Investors 1.8% -65% $25,840,000 -$56,626,396 2,000,000 -69% Capital World Investors 30 Sep 2025

As of 31 Dec 2025, 237 institutional investors reported holding 95,516,854 shares of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR). This represents 83% of the company’s total 115,301,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 16,796,979 +0.16% 0.01% $217,184,938
BlackRock, Inc. 12% 13,541,448 -2.9% 0% $175,090,922
VANGUARD GROUP INC 9.5% 10,958,209 +4.8% 0% $141,689,643
Soleus Capital Management, L.P. 7.4% 8,530,665 -12% 4.7% $110,301,498
MORGAN STANLEY 4.4% 5,069,895 +453% 0% $65,553,743
STATE STREET CORP 2.2% 2,577,239 -1.3% 0% $33,323,700
GEODE CAPITAL MANAGEMENT, LLC 2.1% 2,476,646 +0.07% 0% $32,028,911
Quantinno Capital Management LP 1.7% 2,010,248 +32% 0.05% $25,992,507
RENAISSANCE TECHNOLOGIES LLC 1.2% 1,387,754 +29% 0.03% $17,943,659
Palo Alto Investors LP 1.1% 1,298,964 +3.4% 2.3% $16,795,605
Nuveen, LLC 1.1% 1,273,349 -25% 0% $16,464,403
JACOBS LEVY EQUITY MANAGEMENT, INC 1.1% 1,223,755 +1093% 0.06% $15,823,152
GOLDMAN SACHS GROUP INC 1% 1,178,045 +30% 0% $15,232,122
BAILLIE GIFFORD & CO 0.97% 1,121,274 -0.25% 0.01% $14,498,073
AMERICAN CENTURY COMPANIES INC 0.9% 1,041,532 -15% 0.01% $13,467,009
SCHRODER INVESTMENT MANAGEMENT GROUP 0.88% 1,019,969 +129% 0.01% $13,483,990
C WorldWide Group Holding A/S 0.84% 971,784 0% 0.22% $12,565,000
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 0.8% 927,400 0.02% $11,991,282
Point72 Asset Management, L.P. 0.78% 900,496 +672% 0.02% $11,643,413
ALGERT GLOBAL LLC 0.76% 878,998 +29% 0.18% $11,365,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.76% 876,816 -3.7% 0% $11,337,231
NORTHERN TRUST CORP 0.74% 858,986 -4.3% 0% $11,106,689
D. E. Shaw & Co., Inc. 0.71% 822,385 +69% 0.01% $10,633,438
DIMENSIONAL FUND ADVISORS LP 0.65% 752,143 +33% 0% $9,726,934
SILVERCREST ASSET MANAGEMENT GROUP LLC 0.61% 707,609 +0.22% 0.06% $9,149,384

Institutional Holders of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 19,529,569 $212,895,889 +$6,272,473 $10.90 89
2025 Q4 95,516,854 $1,235,376,652 +$57,865,507 $12.93 237
2025 Q3 91,721,734 $1,185,106,020 -$66,176,848 $12.92 242
2025 Q2 94,465,807 $1,681,500,579 -$12,863,892 $17.80 238
2025 Q1 95,188,552 $1,696,317,176 +$20,032,618 $17.82 224
2024 Q4 91,572,450 $2,728,943,845 -$6,464,722 $29.80 236
2024 Q3 92,870,663 $1,451,669,038 -$11,191,370 $15.63 220
2024 Q2 92,908,941 $1,591,540,722 +$79,622,550 $17.13 229
2024 Q1 89,139,144 $1,393,246,216 -$17,794,761 $15.63 231
2023 Q4 90,513,054 $1,351,320,799 -$31,137,056 $14.93 213
2023 Q3 92,292,343 $1,490,614,876 -$68,391,278 $16.15 219
2023 Q2 90,419,824 $3,752,040,945 +$42,388,515 $41.50 255
2023 Q1 89,476,517 $5,380,865,921 +$285,351,944 $60.14 291
2022 Q4 84,791,322 $6,218,802,349 -$14,733,916 $73.35 292
2022 Q3 83,680,222 $6,357,718,291 +$227,343,238 $75.98 291
2022 Q2 80,381,456 $5,588,033,518 -$44,506,350 $69.50 291
2022 Q1 81,277,607 $6,732,621,045 +$216,637,732 $82.85 293
2021 Q4 79,039,910 $5,935,576,060 +$45,870,200 $75.08 292
2021 Q3 77,530,211 $9,007,824,387 -$79,435,404 $116.17 301
2021 Q2 77,621,320 $17,214,766,292 +$574,320,737 $221.82 351
2021 Q1 75,251,763 $9,945,540,551 +$137,940,262 $132.18 315
2020 Q4 74,207,296 $12,840,473,582 +$248,693,042 $173.04 348
2020 Q3 73,245,441 $8,150,888,382 +$548,147,986 $111.31 272
2020 Q2 69,147,487 $4,099,622,932 -$81,841,604 $59.30 257
2020 Q1 70,405,458 $4,739,588,144 +$74,841,616 $67.34 260
2019 Q4 69,182,535 $5,829,865,247 +$164,443,633 $84.27 256
2019 Q3 66,719,381 $4,988,905,238 +$90,608,393 $74.78 233
2019 Q2 65,861,063 $4,162,579,908 +$194,738,922 $63.23 190
2019 Q1 63,569,972 $3,062,108,451 +$300,901,329 $48.17 195
2018 Q4 57,301,030 $1,918,395,943 +$53,781,587 $33.48 162
2018 Q3 54,688,021 $2,865,670,263 +$204,094,768 $52.40 173
2018 Q2 51,789,754 $1,621,010,556 +$259,146,142 $31.30 159
2018 Q1 44,010,189 $959,322,549 +$148,501,027 $21.80 128
2017 Q4 37,435,567 $756,203,558 +$13,057,344 $20.20 124
2017 Q3 36,815,555 $730,830,514 +$98,783,340 $19.85 103
2017 Q2 31,878,023 $551,480,454 +$204,314,280 $17.30 83
2017 Q1 20,224,271 $164,053,284 +$27,070,509 $8.10 68
2016 Q4 20,282,026 $159,204,948 +$10,262,044 $7.85 73
2016 Q3 18,826,170 $160,713,151 -$21,836,369 $8.54 62
2016 Q2 19,435,597 $226,808,591 +$67,471,069 $11.67 65
2016 Q1 13,616,633 $196,972,145 +$32,373,235 $14.48 56
2015 Q4 11,312,689 $249,219,971 +$248,824,971 $22.36 47
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .